Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

20041,340 citationsJournal Articlebronze Open Access

Authors

John B. Buse · Diabetes Care Center

Robert R. Henry · University of California, San Diego

Jenny Han · Amplyx Pharmaceuticals (United States)

Dennis Dong Hwan Kim · Amplyx Pharmaceuticals (United States)

Mark Fineman · Amplyx Pharmaceuticals (United States)

Alain Baron · Amplyx Pharmaceuticals (United States)

Abstract

Exenatide significantly reduced HbA(1c) in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea. Exenatide was generally well tolerated and was associated with weight loss.

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 27, Issue 11, pp. 2628-2635

DOI: 10.2337/diacare.27.11.2628

Field-Weighted Citation Impact: 47.50